YELLOW FEVER VIRUS VACCINE SERUM: 12-MONTH (IGG) BLEED
We are pleased to make available a liquid preparation of serum obtained from a recipient of Yellow Fever virus donor vaccine (17D strain), 12 months post immunisation. It is suitable as a source of anti-YF IgG antibodies. Yellow Fever virus sera can be used as a diagnostic immunoassay control and in vaccine R&D, for both YFV assays and to investigate assay cross-reactivity with other flaviviruses.
Yellow fever is an acute haemorrhagic disease caused by the Yellow Fever virus (YFV), a a mosquito-borne member of the Flaviviridae family of viruses. It is closely related to dengue, Japanese encephalitis, West Nile, and Zika viruses. Clinical symptoms of the disease include fever, muscle pain, nausea and vomiting. In a small percentage of patients, the liver and kidneys are affected leading to jaundice, and in some cases death. In the late 1930’s a safe and effective, attenuated vaccine was developed against the YFV, which confers long-term immunity. Since its introduction, the vaccine has been used successfully to immunize individuals in areas where YFV is endemic. However, vaccination coverage is sparse and lack of immunity continues to contribute to widespread outreaks. Increasing numbers of travelers to and from endemic areas and outbreaks near major urban areas have heightened concern for the possible introduction and spread of the virus into the US and other countries.
Diagnosis of yellow fever is complicated by the fact that early symptoms of the infection can be confused with other haemorrhagic diseases including Dengue, Ebola and Zika. Differential diagnosis is therefore an important consideration in areas where other flaviviruses such as Dengue and Zika co-circulate.
The Native Antigen Company offers a range of recombinant Yellow Fever virus antigens, highly specific monoclonal antibodies and donor sera from vaccine recipients to support research into YFV infection and assay development.